Article info
Original research
Analytical validation of GMEX rapid point-of-care CYP2C19 genotyping system for the CHANCE-2 trial
- Correspondence to Dr Yongjun Wang; yongjunwang{at}ncrcnd.org.cn
Citation
Analytical validation of GMEX rapid point-of-care CYP2C19 genotyping system for the CHANCE-2 trial
Publication history
- Received January 13, 2021
- Revised March 25, 2021
- Accepted April 8, 2021
- First published May 5, 2021.
Online issue publication
June 28, 2021
Article Versions
- Previous version (5 May 2021).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.